Testosterone
- Generic Name
- Testosterone
- Brand Names
- Androderm, Androgel, Axiron, Fortesta, Natesto, Striant, Testim, Testopel, Vogelxo
- Drug Type
- Small Molecule
- Chemical Formula
- C19H28O2
- CAS Number
- 58-22-0
- Unique Ingredient Identifier
- 3XMK78S47O
- Background
Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism. Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual characteristics.
Testosterone was isolated from samples and also synthesized in 1935.
- Indication
Testosterone is indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.
- Associated Conditions
- Hypergonadotropic Hypogonadism, Hypogonadotrophic Hypogonadism, Idiopathic Hypogonadotropic Hypogonadism, Puberty, Delayed, Inoperable, metastatic Breast cancer
Sexual Effects of Transdermal or Vaginal Testosterone
- Conditions
- Female Sexual DysfunctionPostmenopausal SymptomsTestosterone DeficiencyTestosterone Adverse Reaction
- Interventions
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- University of Sao Paulo General Hospital
- Target Recruit Count
- 132
- Registration Number
- NCT06794346
- Locations
- 🇧🇷
Flavia Fairbanks, São Paulo, SP, Brazil
Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance
- Conditions
- Localized Prostate CarcinomaStage I Prostate Cancer AJCC v8Stage II Prostate Cancer AJCC v8Stage III Prostate Cancer AJCC v8
- Interventions
- Procedure: Biopsy of ProstateProcedure: Biospecimen CollectionProcedure: Magnetic Resonance ImagingOther: Patient ObservationOther: Questionnaire Administration
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 600
- Registration Number
- NCT06733350
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
EndoPAT Device for Endothelial Dysfunction in ED
- Conditions
- Erectile DysfunctionHypogonadism, MaleEndothelial Dysfunction
- Interventions
- Drug: Daily low-dose PDE5 inhibitor therapy
- First Posted Date
- 2024-12-06
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 120
- Registration Number
- NCT06720597
- Locations
- 🇺🇸
UCI Urology | Men's Health Center, Newport Beach, California, United States
Puberty, Testosterone, and Brain Development
- Conditions
- Gender IdentityGender Dysphoria in Adolescents and AdultsHeadacheTransgender
- Interventions
- First Posted Date
- 2024-11-01
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 100
- Registration Number
- NCT06670053
- Locations
- 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
TESTO-TRIAL: Use of Testosterone in Critically Ill Patients
- Conditions
- Weaning FailureMuscle WeaknessMechanical Ventilation ComplicationICU Acquired WeaknessMobility Limitation
- Interventions
- Other: Sesame oil (3ml)
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Leticia Maria Defendi Barboza Marson
- Target Recruit Count
- 94
- Registration Number
- NCT06592144
- Locations
- 🇧🇷
Hospital Estadual Serrana, Serrana, SP/Brazil, Brazil
Adaptions and Resiliency to Multi-Stressor OpeRations
- Conditions
- Musculoskeletal InjuryHypogonadism
- Interventions
- Other: Multi-Stressor TrainingDrug: Placebo Patch
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Bradley Nindl
- Target Recruit Count
- 120
- Registration Number
- NCT06455969
- Locations
- 🇺🇸
Neuromuscular Research Laboratory, Pittsburgh, Pennsylvania, United States
Androgen Effects on the Reproductive Neuroendocrine Axis
- Conditions
- TransgenderismReproductive Issues
- Interventions
- First Posted Date
- 2024-06-10
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 60
- Registration Number
- NCT06450405
- Locations
- 🇺🇸
University of California San Diego, San Diego, California, United States
Comparing Direct and Indirect Detection Methods of Multiple Routes of Testosterone Administration
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Sports Medicine Research and Testing Laboratory
- Target Recruit Count
- 14
- Registration Number
- NCT06393634
- Locations
- 🇺🇸
Sports Medicine Research and Testing Laboratory, South Jordan, Utah, United States
Estradiol and Testosterone Subdermal Implants for Menopause Treatment (ESTIME)
- Conditions
- MenopauseTestosterone DeficiencyEstrogen Deficiency
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- University of Sao Paulo General Hospital
- Target Recruit Count
- 140
- Registration Number
- NCT06343870
Single-Dose Pharmacokinetics of Oral Testosterone Undecanoate With and Without Concomitant Inhibition of UGT2B17
- Conditions
- Hypogonadism, Male
- Interventions
- Dietary Supplement: Curcumin
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 10
- Registration Number
- NCT06312761
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.